Patents Examined by Kahsay Habte
  • Patent number: 10947242
    Abstract: The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, such as neurological and psychiatric disorders.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: March 16, 2021
    Assignee: Janssen Pharmaceutica, NV
    Inventors: Yves Emiel Maria Van Roosbroeck, Frans Alfons Maria Van den Keybus, Gary John Tresadern, Petrus Jacobus Johannes Antonius Buijnsters, Adriana Ingrid Velter, Edgar Jacoby, Gregor James Macdonald, Henricus Jacobus Maria Gijsen, Abdellah Ahnaou, Wilhelmus Helena Ignatius Maria Drinkenburg
  • Patent number: 10941127
    Abstract: The invention relates to 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: March 9, 2021
    Assignee: Albireo AB
    Inventors: Per-Göran Gillberg, Jan Mattsson, Ingemar Starke, Santosh S. Kulkarni
  • Patent number: 10940152
    Abstract: Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: March 9, 2021
    Assignee: SIGNAL PHARMACEUTICALS, LLC
    Inventors: Matthew Alexander, Sogole Bahmanyar, John Frederick Boylan, Joshua Hansen, Dehua Huang, Robert Hubbard, Brandon Jeffy, Jim Leisten, Mehran Moghaddam, Raj K. Raheja, Heather Raymon, Kimberly Schwarz, Marianne Sloss, Eduardo Torres, Tam Minh Tran, Shuichan Xu, JingJing Zhao
  • Patent number: 10941123
    Abstract: The present invention relates to a triazine precondensate according to the general formula (I) where R1 means Q1 or a moiety of the formula R3—N—R4 connected with the nitrogen atom to the triazine ring of the structure of formula (I), where R9 means Q1 or a moiety of the formula R7—N—R8 connected with the nitrogen atom to the triazine ring of the structure of formula (I), where R2, R3, R4 and R6 mean independently from each other H, Q1 or (i), R7 and R8 mean independently from each other H, Q1, (ii) or (iii) or (i), R10 and R11 mean independently from each other R7 or R8; R5 means linear or branched C2-C20-alkyl that can be interrupted by one or more oxygen atoms, sulphur atoms, substituted or non-substituted nitrogen atoms.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: March 9, 2021
    Assignee: Borealis Agrolinz Melamine GmbH
    Inventors: Herbert Gabriel, René Dicke, Helmut Puchinger
  • Patent number: 10941147
    Abstract: The present invention relates to a compound of formula I, 1-1 or 1-2 wherein R1 is hydrogen, lower alkyl, lower alkyl substituted by halogen, halogen, lower alkoxy, or lower alkoxy substituted by halogen; R1 may be different if n=2 or 3 n is 1, 2 or 3 Ar is a six membered heteroaryl group, selected from wherein R2 is hydrogen, lower alkyl, lower alkyl substituted by halogen, halogen or lower alkoxy; R3 is hydrogen or halogen; or to a pharmaceutically active acid addition salt thereof. The compounds may be used for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: March 9, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bjoern Bartels, Roland Jakob-Roetne, Anja Limberg, Werner Neidhart, Hasane Ratni, Michael Reutlinger, Jérôme Charles Sarie, Greta Vastakaite
  • Patent number: 10934270
    Abstract: Disclosed are new small molecules having a substituted quinazoline core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising the small molecules or activated glucocerebrosidase conjugated to the small molecules, which compositions may be administered in methods of treating diseases or disorders associated with glucocerebrosidase activity, including neurological diseases and disorders such as Gaucher's disease and Parkinson's disease.
    Type: Grant
    Filed: November 7, 2019
    Date of Patent: March 2, 2021
    Assignee: Northwestern University
    Inventors: Dimitri Krainc, Richard B. Silverman, Jianbin Zheng
  • Patent number: 10934263
    Abstract: The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof: The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, cough, itch, and neurogenic inflammation.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: March 2, 2021
    Assignee: Nocion Therapeutics, Inc.
    Inventors: Bridget McCarthy Cole, James Lamond Ellis
  • Patent number: 10927126
    Abstract: Disclosed herein are thieno[2,3-b:5,4-c?]dipyridin-8-amine and pyrido[4?,3?:4,5]thieno[2,3-c]pyridazin-8-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: February 23, 2021
    Assignee: Vanderbilt University
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Darren W. Engers, Alison R. Gregro, Kayla Temple, Paul K. Spearing, Madeline F. Long, Julie L. Engers
  • Patent number: 10927118
    Abstract: A class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the treatment of influenza.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: February 23, 2021
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Changhua Tang, Qingyun Ren, Junjun Yin, Kai Yi, Yibo Lei, Yejun Wang, Yingjun Zhang
  • Patent number: 10919927
    Abstract: The present invention provides immune stimulating macrolide of formula (I). The macrolide has utility in treating viral diseases and cancer.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: February 16, 2021
    Assignee: ISR IMMUNE SYSTEM REGULATION HOLDING AB (PUBL)
    Inventors: Ola Winqvist, Robert Wallin, Emma Lindh, Matt Gregory, Steven Moss
  • Patent number: 10919912
    Abstract: The present invention relates to tricyclic heterocycles of Formula (I): which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: February 16, 2021
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Andrew P. Combs, Richard B. Sparks, Thomas P. Maduskuie, Jr., James D. Rodgers
  • Patent number: 10919916
    Abstract: Compounds, pharmaceutical formulations, and methods of treating bacterial infections are disclosed.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: February 16, 2021
    Assignee: Bill & Melinda Gates Foundation
    Inventors: Xianfeng Li, Christopher S Lunde, Robert T Jacobs, Vincent S Hernandez, Yi Xia, Jacob J Plattner, Kathy Jingyuan Cao, Yong-Kang Zhang, Matthew Perry
  • Patent number: 10919914
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: February 16, 2021
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Catherine A. Evans, Martin R. Tremblay
  • Patent number: 10919890
    Abstract: The present invention discloses salts of a Compound 1: useful in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: February 16, 2021
    Assignee: GALAPAGOS NV
    Inventors: Nicolas Luc Sabourault, Piet Wigernick
  • Patent number: 10913752
    Abstract: The present invention provides bivalent inhibitors of BET bromodomains, such as compounds of Formulae (I), (II), (III), (IV), (V), and (VI). Some bromdomain-containing proteins (e.g., BRD4) have a tandem bromodomain primary structure comprising more than one bromodomain binding site (e.g., BRD4 comprises BD1 and BD2). Bivalent inhibitors of BET bromodomains provided herein can target bromodomains through advantageous multivalent interactions, and can therefore can be to treat diseases or conditions associated with bromodomain-containing proteins. The present also provides pharmaceutical compositions and kits comprising the inventive compounds, as well as methods of using the inventive compounds.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: February 9, 2021
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: James E. Bradner, Jun Qi, Minoru Tanaka, Justin M. Roberts
  • Patent number: 10899736
    Abstract: This invention relates to processes and intermediates for making {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, useful in the treatment of diseases related to the activity of Janus kinases (JAK) including inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: January 26, 2021
    Assignee: Incyte Corporation
    Inventors: Dengjin Wang, Pingli Liu, Yongzhong Wu, Jiacheng Zhou
  • Patent number: 10889579
    Abstract: The present disclosure provides a class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables R1, R1?, R2, R2?, R3, R4, R5, R6, R7, and b of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A? plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, and other central nervous system conditions.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: January 12, 2021
    Assignee: Amgen Inc.
    Inventors: Matthew P. Bourbeau, Paul E. Harrington, Qingyian Liu
  • Patent number: 10889581
    Abstract: The present disclosure provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A, R1, R2, R2?, R3, R4, and R5 of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A? plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, and other central nervous system conditions.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: January 12, 2021
    Assignee: Amgen Inc.
    Inventors: Jennifer R. Allen, Albert Amegadzie, Matthew P. Bourbeau, Jian J. Chen, Michael J. Frohn, Paul E. Harrington, Jonathan D. Low, Vu V. Ma, Thomas T. Nguyen, Alexander Pickrell, Corey Reeves
  • Patent number: 10892802
    Abstract: A method of providing spatial diversity for critical data delivery in a beamformed mmWave small cell is proposed. The proposed spatial diversity scheme offers duplicate or incremental data/signal transmission and reception by using multiple different beams for the same source and destination. The proposed spatial diversity scheme can be combined with other diversity schemes in time, frequency, and code, etc. for the same purpose. In addition, the proposed spatial diversity scheme combines the physical-layer resources associated with the beams with other resources of the same or different protocol layers. By spatial signaling repetition to avoid Radio Link Failure (RLF) and Handover Failure (HOF), mobility robustness can be enhanced. Mission-critical and/or time-critical data delivery can also be achieved without relying on retransmission.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: January 12, 2021
    Assignees: Rohm and Haas Electronic Materials LLC, Dow Global Technologies LLC
    Inventors: Lingli Duan, Chen Chen, Shaoguang Feng, Zukhra I. Niazimbetova, Maria Anna Rzeznik
  • Patent number: 10882847
    Abstract: Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein R1, R3a, R3b, R4a, R4b, G1, G2, G2, G3, G4, m1, m2, m3, m4, L1, L2 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: January 5, 2021
    Assignee: ARAXES PHARMA LLC
    Inventors: Liansheng Li, Jun Feng, Yun Oliver Long, Pingda Ren, Yi Liu